Reporting from the 62nd ASH Annual Meeting, Michael Heuser features the results from two trials looking at the response rate when adding venetoclax to standard therapy, in older patients with AML and in high-risk MDS patients.
He also reports interesting results about the use of anti-CD47 antibody magrolimab combined with azacitidine in a patient's population where 73% presented with a TP53 mutation.
Abstracts:
- 25: Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
- 330: The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results
- 656: Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study